You are on page 1of 4

Market Outlook

India Research
February 23, 2012

Dealers Diary
Indian markets are expected to open in the red tracking negative cues worldwide. The Asian stocks have opened in the red following uninspired economic and corporate earnings news which added to the cautious sentiments. European stocks closed lower on Wednesday, as worse than expected German service and manufacturing data combined with additional Greek rating cuts weighed on equities. Fitch has downgraded Greece's credit rating to 'C' from 'CCC' following Eurozone agreement on a second bailout for the country. Also Fitch mentioned that chances of a default are highly likely in the near term. The weakness on Wall Street was partly due to the release of a report showing a contraction in private sector activity in the eurozone, which added to recent concerns about a recession. However another report showing a notable increase in existing home sales in the month of January provided support to the markets. Meanwhile, investors are likely to keep a close eye on the US Labor Department's report on weekly jobless claims which is expected to edge up to 355,000 in the week ended February 18th from the previous week's 348,000.

Domestic Indices BSE Sensex Nifty MID CAP SMALL CAP BSE HC BSE PSU BANKEX AUTO METAL OIL & GAS BSE IT Global Indices Dow Jones NASDAQ FTSE Nikkei Hang Seng Straits Times Shanghai Com

Chg (%)

(Pts)

(Close)

(1.5) (283.4) 18,145 (1.8) (101.8) (3.5) (228.7) (3.2) (233.1) (0.8) (50.7) (2.7) (216.2) 5,505 6,376 6,969 6,328 7,753

(3.8) (490.0) 12,349 (1.6) (159.8) 10,171 (4.3) (543.4) 12,115 (0.8) 0.5
Chg (%)

(69.2) 28.1
(Pts)

8,773 6,285
(Close)

(0.2) (0.5) (0.2) 1.0 0.3 (1.0) 0.9

(27.0) 12,939 (15.4) (11.7) 91.0 (29.5) 22.2 2,933 5,917 9,554 2,996 2,404

Markets Today
The trend deciding level for the day is 18,255/5,542 levels. If NIFTY trades above this level during the first half-an-hour of trade then we may witness a further rally up to 18,414 18,683/5,593 5,681 levels. However, if NIFTY trades below 18,255/5,542 levels for the first half-an-hour of trade then it may correct up to 17,986 17,827/5,454 5,404 levels.
Indices SENSEX NIFTY S2 17,827 5,404 S1 17,986 5,454 PIVOT 18,255 5,542 R1 18,414 5,593 R2 18,683 5,681

70.6 21,549

Indian ADRs Infosys Wipro ICICI Bank HDFC Bank

Chg (%)

(Pts)

(Close)

0.9 1.3 (3.0) (3.1)

0.6 0.1 (1.2) (1.1)

$60.1 $11.3 $38.6 $34.6

News Analysis

IOB to receive `1,978cr form GOI, LIC Result Preview: Ranbaxy Labs, ABB, Aventis Pharmaceuticals - 4QCY2011
Refer detailed news analysis on the following page

Advances / Declines Advances Declines

BSE

NSE

769 2,208 106

242 1,293 37

Net Inflows (February 21, 2012)


` cr FII MFs Purch 4,094 634 Sales 2,599 972 Net 1,495 (338) MTD 15,311 (1,683) YTD 26,392 (3,537)

Unchanged

Volumes (` cr) BSE NSE

3,853 18,502

FII Derivatives (February 22, 2012)


` cr
Index Futures Stock Futures

Purch 6,881 9,859

Sales 7,228 10,555

Net (347) (696)

Open Interest 22,165 32,720

Gainers / Losers
Gainers Company
Tata Comm. Coromandel Int. Gitanjali Gems Sun TV Network Container Corp.

Losers Company
Lanco Infratech United Spirits GMR Infra. IRB Infra. Voltas

Price (`)
254 276 406 331 1,015

chg (%)
6.7 3.2 3.2 2.8 2.6

Price (`)
20 571 29 186 103

chg (%)
(16.8) (14.3) (11.5) (10.8) (10.5)

Please refer to important disclosures at the end of this report

Sebi Registration No: INB 010996539

Market Outlook | India Research

IOB to receive `1,978cr form GOI, LIC


Indian Overseas Bank (IOB) is expected to receive capital infusion worth `1,675cr from Government of India (GOI) and `303cr from Life Insurance Company (LIC). The bank will be issuing equity shares up to 171,232,876 to GOI and 30,937,467 to LIC against this capital infusion. The capital infusion will be at fixed price of `97.82 per equity share (including premium of `87.82). The tier-I ratio which stands at a low 6.7% (excluding 9M profits) as of 3QFY2012 is expect to be propelled up on account of this capital infusion. We currently have a Neutral recommendation on the stock.

Result Preview - 4QCY2011 Ranbaxy Laboratories


For the quarter, Ranbaxy is expected to report sales and profit of `2,900cr and net profit of `589cr, respectively. OPM is expected to come in around 33.2%. Results would be driven by Lipitor sales. We maintain our Neutral view on the stock.

ABB
For 4QCY2011, we expect ABB India (ABB) to post strong top-line growth of 16.4% yoy to `2,412cr, driven by the company's balanced performance across all segments. EBITDA margin is likely witness a sharp uptick of 352bp yoy to 5.1% (4QCY2010 margins were suppressed by higher provisioning on account of rural electrification projects). Also, on a qoq basis, we expect margins to improve by ~120bp. Aided by strong revenue growth and an extremely low base of the prior-year period, ABB's bottom line is expected to jump eight-fold to `61.9cr. At CMP the stock trades at rich valuations of 48.1x CY2012E EPS. We maintain Sell on the stock.

Aventis Pharmaceuticals
For the quarter, Aventis is expected to report sales and net profit growth of 15.7% yoy and 39.7%, respectively. Thus, the company is expected to end the quarter with net sales and profit of `332cr and `40.3cr, respectively. OPM is expected to come in at 13.5%, an expansion of 640bp yoy. We maintain our Reduce rating on the stock with a target of `1,937.

February 23, 2012

Market Outlook | India Research

Quarterly Bloomberg Brokers Consensus Estimates


Ranbaxy - Consolidated (23/02/2012)
Particulars (` cr) Net sales EBITDA EBITDA margin (%) Net profit 4QCY11E 2,811 597 21.2 285 4QCY10 2,066 (174) -8.4 (94) y-o-y (%) 36 3QCY11 2,023 174 8.6 (457) q-o-q (%) 39 243

Economic and Political News


OMOs better tool to ease liquidity: PMEAC Decontrol urea prices, raise excise duty: PMEAC Government planning 63,000MW nuclear power capacity by 2032

Corporate News

Chinese banks to refinance `6,000cr RCOM debt BPCL to up Saudi imports in FY2013, cut Iran volumes Hero MotoCorp partners with US firm, Erik Buell Racing (EBR) State Bank of India to bail out Kingfisher US to import cancer drug from Sun Pharma

Source: Economic Times, Business Standard, Business Line, Financial Express, Mint

Results Calendar
23/02/2012 Ranbaxy, ABB, Gujarat Gas, Aventis

February 23, 2012

Market Outlook | India Research

Research Team Tel: 022 - 39357800

E-mail: research@angelbroking.com

Website: www.angelbroking.com

DISCLAIMER
This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Angel Broking Limited, its affiliates, directors, its proprietary trading and investment businesses may, from time to time, make investment decisions that are inconsistent with or contradictory to the recommendations expressed herein. The views contained in this document are those of the analyst, and the company may or may not subscribe to all the views expressed within. Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Limited endeavours to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly. Angel Broking Limited and its affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past. Neither Angel Broking Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information. Note: Please refer to the important `Stock Holding Disclosure' report on the Angel website (Research Section). Also, please refer to the latest update on respective stocks for the disclosure status in respect of those stocks. Angel Broking Limited and its affiliates may have investment positions in the stocks recommended in this report.

February 23, 2012